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INTRODUCTION
This article, w ritten  on the  occasion of Dr. Avexy Sand­
berg’s 75th b irthday, is in tended  to give a general and 
short overview of the  cytogenetic data about testicular 
germ cell tum ors of adolescents and adults we obtained 
from 1983 till now. The first and  last author of this m anu­
script visited Dr. Sandberg’s lab in 1984 to improve their 
skills in  culturing and karyotyping solid tumor cells. 
Knowing that cancer and progression of cancer is caused 
by genetic changes (i.e. changes at the chromosomal or 
gene level), we investigated the karyotypes of about 140 
testicular germ cell tum ors of the adult and adolescent 
male (TGCTs). The chrom osom al analyses of these tumors 
m ay shed light on oncogenesis, tum or progression, patho­
genetic re la tionship , and therapy-related differentiation. 
We w ill focus on w h a t we th ink  our cytogenetic data have 
taught us about the progression of TGCTs. Of course, a 
way of th ink ing  is always influenced or even determined 
by the results of others. This article is not intended as a 
review  of the literature. For th is the reader should consult 
a recent and excellent review  by Sandberg et al. [1], the 
m anuscrip ts of others, and  our previous publications 
about germ cell tumors.
TESTICULAR GERM CELL TUMORS
Germ cell tum ors of adult and  adolescent males are rare 
neoplasms, located in  the gonads (testis) and in extragonadal 
sites (e.g. retroperitoneum, mediastinum, and brain). Primary 
testicular germ cell tum ors of adolescents and  adults 
(TGCTs) can be d iv ided  clinically and  morphologically
into two distinct entities [2,3]: seminomas (SEs), reflecting 
differentiation along the germ cell lineage, and nonsemi- 
nomatous TGCTs or nonseminomas (NSs), of which pluripo- 
tent embryonal carcinoma (EC) cells are the stem cells. EC 
may differentiate into extraembryonic cell types resulting 
in choriocarcinoma (GH) and yolk sac tumor (YS) or along 
the lines of embryonic cells and tissues, resulting in imma­
ture teratoma (IT) and m ature teratom a (MT) . Most NSs 
have a mixed histology with the different histologic elements 
geographically separated or truly mixed. A minority of 
TGCTs contain both a SE and NS component, the combined 
tumors (CTs). Most TGCTs are thought to be derived from 
dysplastic germ cell precursors that progress to carcinoma 
in situ (CIS) [4]. It is suggested that the initiation of TGCTs 
starts early in  life, probably before birth  [5,6].
Whether and to what degree SEs and NSs are pathoge- 
netically related is still a m atter of debate. In essence, two 
models exist about the pathogenetic relationship between 
SEs and NSs [2,3,7-9]. In the first model, the histogenesis 
of SEs is assumed to diverge from that of NSs at an early 
stage. The neoplastic germ cells may either give rise to SE, 
reflecting germ cell differentiation or may differentiate 
into embryonic or extraembryonic tissues resulting in  NS. 
According to this model the neoplastic pathways of SEs 
and NSs are different, w ith  no or only limited crossover 
[[7)y for review).
The second model suggests that SEs and NSs have a 
common origin with a single neoplastic pathway, in which 
SE may present an intermediate stage in development to­
wards NS. According to this view, SE may either be an 
end stage in differentiation, or alternatively may progress 
to a NS phenotype. As a consequence, SEs and NSs may 
be closely related.
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ONCOGENESIS AND PATHOGENESIS OF SEMINOMAS 
AND NONSEMINOMAS
To answer questions raised above about oncogenesis and 
pathogenesis, we investigated the karyotypes of five cases 
of CIS [10,11], 32 cases of SEs [12,13], 70 cases of NSs 
[12,14], and 31 cases of residual mature teratomas (RMTs) 
following chemotherapy [15,16]. Table 1 shows the number
0165-4608/97/$17.0G 
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Table 1 Normal c o p ie s  of chromosomes and i(12p) per case in. CIS
Case 1 2 3 4 5 6 7 a 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y i(12p) N*
1 3 2 3 4 2 2 3 5 5 3 3 ?4 3 2 5 2 2 3 1 ?B 6 4 3 - - 79
2 3 3 3 1 2 3 3 4 - 4 2 3 2 2 1 3 3 2 2 4 1 3 3 2 61
3 3 3 2 1 3 2 4 2 2 2 3 2 3 2 2 2 2 3 2 2 1 2 2 - 2 55
4 3 3 3 3 2 2 3 4 3 2 2 3 3 3 3 3 3 2 3 2 4 4 2 2 2 68
5 2 1 2 2 2 3 3 3 3 1 2 2 2 2 1 2 2 - 2 2 3 2 2 1 ?1 ?65
Total 14 12 13 11 11 12 16 18 13 12 12 14 13 11 12 12 12 10 10 16 15 15 12 5 5
N* = modal chromosome number, structural abnormal chromosomes included.
of normal copies o f  chromosomes, the num ber of i(12p) 
and the modal ch rom osom e num ber of the 5 cases of CIS. 
The modal chrom osom e num ber ranged from 55 to 79; 
with an average of 66 [11], In the 32 SEs the modal chromo­
some number ranged from 58 to 112 with an average of 73.4 
and in die 70 NSs, f ro m  50 to 113; w ith an average of 65.0 
[12]. Figures 1, 2, a n d  3 show karyotypes of a case of CIS, 
SE, and NS, respectively ,
For the SEs, N Ss, an d  RMTs we determ ined for each 
tumor and chrom osom e the modal number of short and 
long arms. Parts of chrom osom al arms involved in  struc­
tural abnormalities w e re  registered as whole arms if they 
represented 50% or m ore of the total arm length. The
modal num ber of short arms plus long arms divided by 2 re­
vealed the average m odal n u m b e r  of chromosomes. The 
average num ber of sex chrom osom es for each tum or was 
m ultiplied by  2 to allow com parison with the autosomes 
[12-16].
Figure 4 shows the  average m odal num ber of short and 
long arms for each chrom osom e in  the SEs, NSs, and 
RMTs, The average n u m b er  of copies of the different chro­
mosomes w as highly sim ilar in  SEs and NSs (Spearman 
rank correlation 0,812, P <  0.001) [12]. We found both in 
SEs and  NSs chrom osom e n u m b ers  in  the triploid range 
with a significantly h igher n u m b er  of chromosomes in  SEs 
than in  NSs. These data are in  agreement w ith ploidy studies
Figure 1 Representative karyotype of a case of CIS with the following karyotype description: 69,XX,
-Y ,-5 ,-6 ,4 -7 ,+ 8 ,-10 , - 11, +i(12)[plO)X2 ,-14,-18,-20,+21,+22, + 22,+mar.
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Figure 2 Representative karyotype of a case of SE with the following karyotype description: G8,XX,-Y, 
+add(2)(pll),—4,-5, +der(7)t(l;7)(q21;q32),+i(8)(ql0)J-9,der(9;17)(plQ;ql0], —ll,add(ll)(ql3), +der(12) t(12;?;9) 
(pl3;?;ql2),~13, + 14,+15,—17, —18Jdel[lÜ](q21),4-der(19)L(9;19](ql2:pl2), —20, —20, + 21,+22.
on SEs and NSs, showing, on average, a higher DNA index 
(DI) in  SE than  in NS [8,17-20]. We found the median DI 
of CIS about the same as that of SEs and higher than the DI 
of invasive NSs [19]. Together w ith  our finding of a very 
similar distribution pattern of the different chromosomes 
in SEs and NSs (Fig. 4] as well as the resemblance in dis­
tribution of breakpoints in SEs and NSs [12] these data fit 
w ith a pathogenetic model of TGCTs suggesting that SEs 
and NSs have a common origin with a single neoplastic 
pathway, with SE constituting an intermediate stage in NS 
development [8,9,12,19]- This view is supported by the cy­
togenetics of a CT we karyotyped. Of three cases of combined 
tumors (CTs) we karyotyped the SE and NS component 
separately [21], In one case the SE and NS component of 
the GT shared eight different structural chromosomal ab­
normalities, indicating that in this tum or the SE and NS 
component are pathologically closely related and have a 
com m on neoplastic pathway for a considerable length. 
Recently we obtained supportive data for the hypothesis 
of a common origin of SEs and NSs using in situ hybrid­
ization w ith  region specific probes on tissue sections [22], 
Our cytogenetic data of TGCTs support the linear pro­
gression m odel [7-9,12] in which SE may be an end stage 
in  differentiation as well as an intermediate stage in the 
developm ent of CIS to NS. Both SEs and NSs are supposed
to be derived from CIS [4], We described the similarities in 
chromosomal pattern between two cases of TGCTs and its 
adjacent CIS [11], These results represent cytogenetic evi­
dence that CIS is clonally related to, and is the precursor 
for, invasive TGCTS. This has been supported using in 
situ hybridization on tissue sections [22,23],
An im portant and early event in the oncogenesis of 
TGCTs is polyploidization of a dysplastic germ cell precur­
sor, resulting in  aneuploid CIS. The progression of CIS 
SE —>NS is accom panied by net loss of chromosomes 
[8,9,12,19]. The CIS karyotypes (Table 1) revealed some 
evidence for karyotype evolution. If polyploidization is a 
very early oncogenetic step one w ould  expect to find, in 
the absence of karyotype evolution, similar numbers of the 
different chromosomes. This is not the case [10,11]. Because 
the number of cases of CIS and the number of analyzed 
metaphases is small, it is rather speculative to derive definite 
conclusions regarding the chromosomal constitution of 
CIS. But it is remarkable that some chromosomes, overrep­
resented in  SEs and NSs, already show a trend of overrep­
resentation (e.g. cliromosomes 7 and 8) in CIS.
i(12p) is the characteristic chromosomal abnormality of 
TGCTs [24]. We found i(12p) in about half of our karyotyped 
cases of CIS (Table 1]. This suggests that i(12p) formation 
is an im portant and early event in  the oncogenesis of
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Figure 3 Representative karyotype of a case of NS with the following karyotype description: GG,XXY 
+Y,i(l)(ql0)f+der(3)t(3;8)(q23;q22),“ 41-5 ,- f l1+7f- 8 , + 1 0 - l l (+m2)(plO)X2f-1 3 l“ 151-1 0 i- 1 8 I+21I“ 22.
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Figure 4 Average modal num­
ber of short and long arms per 
chromosome in a group of 32 SEs 
(thin line)» 70 NSs (dark line), and 
31 RMTs (dotted line}. The aver­
age number of sex chromosomes 
for each case was multiplied by 2 
to allow comparison with the 
autosomes.
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F ig u re  5 Tumor progression model of TGGTs of adults proposed by Oosterhuis et al. [8], supplemented with our 
relevant chromosomal data.
TGCTs, although most likely preceded by polyploidization 
[25], Both the frequency and the num ber of copies of 
i(12p) are higher in NSs than  in SEs [12], We found i(12p) 
in 56% of the SEs and in  83% of the NSs, The average 
num ber of copies in  the SEs was 0,9 and  in the NSs 1.7. 
W hen the linear progression m odel in w hich SE may be an 
end stage in  differentiation as w ell as an intermediate 
stage in th e  development of CIS to NS [7-9] is correct this 
might indicate  tha t an increase in i(12p) copy num ber may 
be related to tum or progression from SE to NS. We and 
others observed aberrations of chromosome 12 in i(12p)- 
negative TGCTs [12,26-28]. FISH studies have shown that 
i(l2p)-negative tumors consistently show amplification of 
12p [29,30]. Our cytogenetic data extended with our molecu­
lar data po in t to an overrepresentation of the region 
1 2 p ll . l~ p l2 .1  [31,32], The consistent overrepresentation 
of I2p  sequences, by i(12pH orm ation or other aberrations 
of chrom osom e 12, indicates that a gene on 12p plays an 
im portant role in  the oncogenesis of TGCTs. However, the 
identification of this gene remains to be established,
The gain and loss of chromosomes during die progression 
of TGCTs, resulting in ne t loss of chromosomal material, is 
nonrandom ; specific chromosomes are overrepresented 
(e.g. 7, 8, 12, 21, and X), and others are underrepresented 
(e.g. 11, 13, 18, and Y) (Fig. 4)[9, 12-16], Although our se­
ries of CIS is small, we have indications that losses and 
gains of chromosomes already occur in CIS [9-11], In situ
hybridization [23] and  DNA flow cytometry studies [33] 
also point to karyotype evolution in  CIS, The autosomes 
that are overrepresented in  TGCTs may harbor growth pro­
moting genes and relevant tum or suppressor genes may be 
located on the underrepresented  chromosomes. In SEs, a 
significantly higher copy num ber of chromosomes 7,15,19, 
and 22 was found and a significantly lower copy number of 
chromosome 17, com pared w ith  NSs. Besides these numer­
ical chromosomal differences we also observed some signif­
icant differences in structural chromosomal abnormalities 
between SEs and NSs [12]. These chromosomal differences 
between SEs and NSs may p lay  a role in tumor progression 
or in the direction of differentiation of SE and NS [8,9,12]. 
Specific over- and underrepresentation of (parts of) chro­
mosomes as detected by conventional karyotyping in 
TGCTs has recently been verified by using comparitive ge­
nomic hybridization [32],
In conclusion, im portan t steps in  the oncogenesis or 
progression of TGCTs are polyploidization, overrepresen­
tation of 12p sequenses, overrepresentation of some specific 
chromosomes or parts of chromosomes, and underrepre­
sentation or retention  of others, resulting in net loss of 
(parts) of chromosomes. This m ultistep process of poly­
ploidization, overrepresentation of 12p sequences and spe­
cific gain, loss, or retention of chromosomes and parts of 
chromosomes results in  a m ore or less characteristic chro­
mosomal pattern for TGCTs (Fig. 4). Figure 5 shows the tumor
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Figure 6 Representative karyotype of a case of RMT with the following karyotype description: 60.XXY, 
add(l)(p34),—4,—5,—9,—10, -ll,+i(12)(pl0)X 21-13 ,~14 ,-15 ,-18J-19 ,-20 ,-22 ,+m ar.
progression model of TGCTs of adults proposed by Ooster- 
huis et al [8], supplem ented w ith  our relevant cytogenetic 
data [12].
i(12p)-formation and over- and underrepresentation of 
chromosomes already occur in CIS. This may suggest that 
karyotype evolution/tum or progression in TGCTs already 
takes place in an early stage of tumor evolution. To sub­
stantiate this notion, it w ould  be of importance to obtain 
more cytogenetic data of CIS adjacent to invasive tumor 
and of CIS before it has progressed to invasiveness. Com­
parison of the different stages of CIS with invasive tumor 
may shed further light on the process of tumor evolution 
in TGCTs.
METASTASIS AND THERAPY-RELATED 
DIFFERENTIATION OF TGCT METASTASES
Cytogenetic comparison of primary tumors and metastases 
may indicate chromosomal changes playing a role in 
tumor progression. Tumor progression is the result of 
clonal evolution of a tum or cell population and is paral­
leled by karyotype evolution [34], Because of clonal evolu­
tion and selection, malignant tumors are genetically 
heterogeneous and contain multiple subpopulations of 
cancer cells. Onty certain subpopulations of tumor cells 
have the capacity to form metastatic lesions [35,36],
Because of the application of s tandard ized  clin ical p ro to ­
cols, we are not able to investigate the chrom osom al p a t­
tern of untreated metastases of NSs. It is only possible to 
study residual lesions following chem otherapy, usually  
RMT. These lesions are com posed of fully differentiated 
tissue [37]. This higher degree of differentiation after che­
motherapy treatment might be because of d irect induction  
of differentiation of tum or cells to fully differentiated  
cells, to selective destruction of cells o ther th an  MT cells, 
or to selection of cells w ith  an inheren t capacity  of spon ta­
neous differentiation or capacity  of therapy  re la ted  differ­
entiation ([2,37-39], for review).
A cytogenetic com parison betw een  NSs and  RMTs m ay 
shed light on w hich  chrom osom al changes p lay  a role in 
tumor progression and on the m echanism (s) of therapy  re­
lated differentiation, although a d istinction  betw een  bo th  
events cannot be made.
We karyotyped 31 RMTs [15,16]. Figure 6 show s one of 
the karyotypes. The average m odal total chrom osom e 
number was 60.5. That all tum or cells from RMT are aneu- 
ploid was demonstrated by using  a dua l param eter flow 
cytometric analysis [40] .We found in  81%  of the RMTs an 
i(12p) chromosome with an average copy num ber of 1.5. 
In NSs and RMTs the total m odal chrom osom e num ber 
does not differ. The m edian DNA index  of p rim ary  NSs 
and lymph node metastases are in the  sam e range [20],
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The average num ber of copies of the different chromo­
somes and parts of chromosomes are highly similar in the 
NSs and  RMTs (Spearman rank  correlation 0.918, P < 
0.001) (Fig. 4), both the frequency and average copy num ­
ber of i(12p) are in  the same range and the distribution of 
chromosomal breakpoints does not differ significantly in 
both series [15].
So our cytogenetic com parison between the series of 70 
NSs and 31 RMTs revealed no significant chromosomal 
differences between the prim ary tum ors and the m é­
tastasés after chemotherapy. This may be explained in differ­
ent ways [15]:
1. In vitro selection, Métastasés result from the selec­
tive growth of specialized subpopulations of cells of 
the primary tum or [35,36]. Culturing the heteroge­
neous primary tum or may select for cells of the 
specific subpopulations tha t finally populate the 
métastasés. U nder the  influence of therapy the meta­
static cells differentiate irrespective of their highly 
abnormal karyotype.
2. Clonal dom inance. The progeny of a single meta­
static clone could eventually overgrow the primary 
tumor. As a result late-stage advanced primary tu­
mors w ould  be biologically similar to distant mé­
tastasés [41]. Both may show  similar karyotypes. 
U nder the influence of therapy the metastatic cells 
differentiate irrespective of their highly abnormal 
karyotype.
3. One w ould  not expect to find chromosomal differ­
ences betw een prim ary NSs and RMTs, w hen m e­
tastasis is no t paralleled by visible chromosomal 
alterations and w hen  RMTs are the result of therapy- 
related induction  of differentiation of cells, irrespec­
tive of their chromosomal pattern.
The chem otherapy related differentiation of RMTs 
m ight be because of selective destruction of cells other 
than MT or to selection of other cells w ith an inherent capac­
ity of (therapy related) differentiation. If, however, RMTs 
are the result of differentiation of selected cells w ith a 
chromosomal constitution allowing differentiation one 
would only expect to find specific chromosomal differences 
betw een prim ary NSs and  RMTs w hen the direction or 
degree of differentiation w ithin NSs is paralleled by visible 
chromosomal changes. W e never found evidence for this 
[42, 43].
In conclusion, primary NSs and metastatic mature rest
have comparable 
chromosomal patterns. We found no cytogenetic evidence 
that specific chrom osom al changes parallel metastasis and 
therapy related differentiation of métastasés. Based on cy­
togenetics, both  induction  of differentiation of (selected) 
cells or selection of cells w ith  capacity to differentiate are 
possible m echanism s for the therapy related differentia­
tion of RMTs.
TGCTS do not have one single or only a few specific chro­
mosomal abnormalities. They show a highly abnormal, more 
or less characteristic, chrom osom al pattern. This pattern 
results from the accum ulation of a restricted scale of chro­
m osom al abnormalities tha t enables the development, sur-
lesions left beh ind  after chem otherapy
vival, and progression of TGCTs. Deviation from this 
pathway leads to a chromosomal pattern not compatible 
with (further) development as a TGCT. The highly restricted 
pattern of chromosomal abnormalities may explain our 
finding of identical or almost identical karyotypes in recur­
rent lesions, compared to primary tumors, in the same 
patient even after several years [44].
Despite their benign histologic appearance RMTs have 
a highly abnormal karyotype not distinguishable from that 
of primary NSs. Thus RMTs should be considered as 
wolves in sheep clothing, which justifies their complete 
surgical removal [45].
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